CONTROLLING NK CELL ANTI-CANCER ACTIVITY: THE ROLE OF NUTRIENTS AND SUPPLEMENTS
CONTROLLING NK CELL ANTI-CANCER ACTIVITY: THE ROLE OF NUTRIENTS AND SUPPLEMENTS
批准号:
8601055
负责人:
MARCO COLONNA
金额:
$19.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2014-12-31
关键词:
AddressApplications GrantsAryl Hydrocarbon ReceptorAzoxymethaneBindingBotanicalsCell LineCellsChemicalsChronicColitisColonCountryDataDendritic CellsDevelopmentDietDysplasiaEpithelialEpithelial Cell ProliferationEpithelial CellsFlavonoidsGene MutationHumanImmuneImmunityImmunologic MonitoringIndolesInflammatoryInterferonsInterleukin-12Interleukin-2LaboratoriesLamina PropriaLesionLeukocytesMalignant NeoplasmsMeasuresMediatingMelanoma CellMesenteryMethanolModelingMouse StrainsMucous MembraneMusNatural Killer CellsNutrientNutritionalOligonucleotidesPhenotypePlasticsPlayPositioning AttributeProductionPropertyQuercetinReagentRecording of previous eventsRoleSmall IntestinesSodium Dextran SulfateStimulusStructure of aggregated lymphoid follicle of small intestineSupplementationTestingTherapeuticTransplantationWorkaryl hydrocarbon receptor ligandbasecancer preventioncancer therapycell typechemokinecytokinedietary supplementsfeedingfruits and vegetablesin vivointerleukin-22lymph nodesmelanomamouse modelnovelpolyphenolpublic health relevanceresearch studysubcutaneoustooltranscription factortumortumor growthtumorigenesis
中文摘要
描述(由申请人提供):自然杀伤细胞通常被视为癌症免疫监测的第一道防线,是免疫介导的癌症排斥反应的关键角色。我们最近描述了一种新的非常规NK细胞亚群,它驻留在粘膜组织中,其特征是产生大量的IL-22。我们将这个新的细胞亚群称为NK-22。尽管这些细胞的来源尚不清楚,它们与传统NK细胞的关系也存在争议,但我们和其他人已经证明,当暴露于炎性细胞因子时,这些细胞可以获得传统NK细胞的典型特征。此外,最近的研究表明,类似的细胞类型在启动肿瘤排斥反应中起着关键作用。我们的初步数据表明,NK-22的发育高度依赖于转录因子芳香烃受体(AHR)。已知AHR结合饮食化合物,如吲哚-3-甲醇(I3C)和类黄酮类,与抗肿瘤活性有关。我们假设,通过膳食补充剂使AHR参与,我们可以操纵NK-22的数量和/或活性。在特定目的1中,我们将在体内检测I3C和黄酮类槲皮素对NK-22的扩增和功能的影响。在特定的目标2中,我们将确定这些补充剂是否影响NK-22在自发和可移植肿瘤模型中的抗肿瘤功能。我们发现了NK-22,对其发育和功能的初步表征做出了贡献,并产生了独特的NK-22特异性试剂以及在几种免疫和非免疫细胞类型中缺乏NK-22或AHR的小鼠品系。因此,我们处于一个独特的位置,可以直接测试据称与抗癌活性相关的特定膳食补充剂对先天免疫细胞监视肿瘤的影响。好了!
英文摘要
DESCRIPTION (provided by applicant): Natural killer cells are generally viewed as a first line of defense in cancer immunosurveillance and are critical players in immune-mediated cancer rejection. We have recently described a new subset of unconventional NK cells that reside in mucosal tissues and are characterized by production of large amounts of IL-22. We refer to this novel cell subset as NK-22. Although the origin of these cells is still unclear and their relationship to conventional NK cells a matter of debate, we and others have shown that these cells can acquire features typical of conventional NK cells when exposed to inflammatory cytokines. Moreover, recent work has suggested that a similar cell type plays a critical role in initiating tumor rejection. Our preliminary data show that NK-22 are highly dependent on the transcription factor aryl hydrocarbon receptor (AHR) for their development. AHR is known to bind dietary compounds such as indol-3-carbinol (I3C) and flavonoids that are associated with anti-tumor activity. We hypothesize that by engaging AHR through dietary supplements, we can manipulate the numbers and or the activity of NK-22. In Specific Aim 1 we will test the effect of I3C and the flavonoid quercetin on NK-22 expansion and function in vivo. In Specific Aim 2 we will determine whether these supplements impact the anti-tumor function of NK-22 in spontaneous and transplantable tumor models. We discovered NK-22, contributed to the initial characterization of their development and function and have generated unique NK-22 specific reagents as well as mouse strains lacking NK-22 or AHR in several immune and non-immune cell types. Therefore, we are in a unique position to directly test the impact of specific dietary supplements allegedly associated with anti-cancer activity on tumor surveillance by innate immune cells. !
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Mucosal Immune Defense Mechanisms of the Urinary Bladder
-
批准号:10587639
-
项目类别:
-
资助金额:$62.28万
-
财政年份:2023
-
负责人:MARCO COLONNA
-
依托单位:
Soluble TREM2 regulation of microglial function in Alzheimer disease
-
批准号:10432584
-
项目类别:
-
资助金额:$43.06万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
-
批准号:10528082
-
项目类别:
-
资助金额:$19.69万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
The protein tyrosine kinase SYK drives innate immune responses against Alzheimer's Disease
-
批准号:10674689
-
项目类别:
-
资助金额:$59.72万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
-
批准号:10623342
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
-
批准号:10446266
-
项目类别:
-
资助金额:$62.45万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
-
批准号:10557870
-
项目类别:
-
资助金额:$59.89万
-
财政年份:2022
-
负责人:MARCO COLONNA
-
依托单位:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
-
批准号:10321553
-
项目类别:
-
资助金额:$41.51万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10477296
-
项目类别:
-
资助金额:$43.23万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10279674
-
项目类别:
-
资助金额:$41.62万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
-
批准号:10539270
-
项目类别:
-
资助金额:$41.03万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Targeting TREM2 to boost anti-cancer therapy
-
批准号:10689150
-
项目类别:
-
资助金额:$43.23万
-
财政年份:2021
-
负责人:MARCO COLONNA
-
依托单位:
Plasticity of Innate Lymphoid Cells: Mechanisms and Biological Impact
-
批准号:10597244
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
-
批准号:10265677
-
项目类别:
-
资助金额:$24.13万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
Plasticity of Innate Lymphoid Cells: Mechanisms and Biological Impact
-
批准号:10363734
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
-
批准号:10219643
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2020
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10371236
-
项目类别:
-
资助金额:$33.39万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10579869
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
Impact of Airway Epithelium on Innate and Adaptive Immunity in the Lung
-
批准号:10113529
-
项目类别:
-
资助金额:$37.16万
-
财政年份:2019
-
负责人:MARCO COLONNA
-
依托单位:
CIS-REGULATORY CIRCUITS FOR ILC FUNCTION AND PLASTICITY
-
批准号:10219921
-
项目类别:
-
资助金额:$65.0万
-
财政年份:2018
-
负责人:MARCO COLONNA
-
依托单位: